Clinical decision support systems for improving diagnostic accuracy and achieving precision medicine by unknown
JOURNAL OF 
CLINICAL BIOINFORMATICS
Castaneda et al. Journal of Clinical Bioinformatics  (2015) 5:4 
DOI 10.1186/s13336-015-0019-3REVIEW Open AccessClinical decision support systems for improving
diagnostic accuracy and achieving precision
medicine
Christian Castaneda1, Kip Nalley2, Ciaran Mannion3, Pritish Bhattacharyya3, Patrick Blake2, Andrew Pecora4,
Andre Goy4 and K Stephen Suh1,4*Abstract
As research laboratories and clinics collaborate to achieve precision medicine, both communities are required to
understand mandated electronic health/medical record (EHR/EMR) initiatives that will be fully implemented in all
clinics in the United States by 2015. Stakeholders will need to evaluate current record keeping practices and
optimize and standardize methodologies to capture nearly all information in digital format. Collaborative efforts
from academic and industry sectors are crucial to achieving higher efficacy in patient care while minimizing costs.
Currently existing digitized data and information are present in multiple formats and are largely unstructured. In the
absence of a universally accepted management system, departments and institutions continue to generate silos of
information. As a result, invaluable and newly discovered knowledge is difficult to access. To accelerate biomedical
research and reduce healthcare costs, clinical and bioinformatics systems must employ common data elements to
create structured annotation forms enabling laboratories and clinics to capture sharable data in real time.
Conversion of these datasets to knowable information should be a routine institutionalized process. New scientific
knowledge and clinical discoveries can be shared via integrated knowledge environments defined by flexible data
models and extensive use of standards, ontologies, vocabularies, and thesauri. In the clinical setting, aggregated
knowledge must be displayed in user-friendly formats so that physicians, non-technical laboratory personnel, nurses,
data/research coordinators, and end-users can enter data, access information, and understand the output. The effort
to connect astronomical numbers of data points, including ‘-omics’-based molecular data, individual genome sequences,
experimental data, patient clinical phenotypes, and follow-up data is a monumental task. Roadblocks to this vision
of integration and interoperability include ethical, legal, and logistical concerns. Ensuring data security and protection
of patient rights while simultaneously facilitating standardization is paramount to maintaining public support. The
capabilities of supercomputing need to be applied strategically. A standardized, methodological implementation
must be applied to developed artificial intelligence systems with the ability to integrate data and information into
clinically relevant knowledge. Ultimately, the integration of bioinformatics and clinical data in a clinical decision
support system promises precision medicine and cost effective and personalized patient care.
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Clinical informatics is the application of informatics and
information technology to support healthcare delivery
services. Its role is rapidly evolving toward providing
better clinical decision-making by integrating state-of-
the-art knowledge with medical record systems [1]. As
medicine moves into an era of personalized treatment
and precision pharmaceuticals, the application of expert-
ise in electronic health/medical record (EHR/EMR) sys-
tems and translational research will enhance operating
efficiencies for hospitals and reduce costs. In reality, the
populating and analyzing of large amounts of accumulat-
ing data in standardized format from EHRs has yet to
happen, since protocols and resources have not yet suffi-
ciently matured. Recognition of the importance of apply-
ing digitized data and information for patient care has
spurred the first class of physicians to become board-
certified in the newly-created subspecialty of clinical
informatics [2].
Bioinformatics is the development of storage, analytic,
and interpretive methods to optimize the transformation
of increasingly voluminous biomedical and genomic data
into proactive, predictive, preventive, and participatory
healthcare [3]. The field of bioinformatics has grown
exponentially, providing a vast amount of information,
information that is largely unstandardized and practically
inaccessible. While problems with semantic medical
term standardization and varied data quality plague clin-
ical informatics, research scientists continue to struggle
with different exchange data types, service ontologies,
and fragmented web services [4,5]. As we move into the
era of the $1,000 genome analysis [6] and the reality of
mandatory EHR [7], the focus of bioinformatics has
shifted from gathering data to analyzing the massive
amounts of available data for direct application in
patient care.
A critical step for achieving precision medicine will be
to integrate old and new data into validated information
and to convert this information into knowledge directly
applicable to diagnosis, prognosis, or treatment. This
will entail developing an integrated knowledge envi-
ronment that continually captures information, grows,
accumulates, organizes, and institutionalizes new infor-
mation, making it accessible to health care providers.
Knowledge accumulated from scientific research and
clinical data contained in EHRs will be shared and will
impact the discovery of novel therapeutic methods and
the application of precision medicine. It now takes
17 years for a laboratory discovery to reach widespread
clinical application [8]. The promise of bioinformatics is
to optimize treatment decisions and enhance outcomes,
by providing immediate access to the patient’s genomic,
laboratory, and EHR information, and by relating that
information to current clinical trials and research.Role of EHR in linking clinical informatics and
bench science
The advantages and disadvantages of EHR have been
debated since passage of the American Recovery and
Reinvestment and the HITECH Acts of 2009 mandated
and incentivized their adoption and use [9]. Although
analysis by the American Medical College of Informatics
have outlined cost, data security concerns, and steep
learning curves as the major barriers to EHR adoption
[10], a majority of health care providers perceive that
implementation and meaningful use of EHR will de-
crease operating costs, decrease error rates, and increase
favorable patient outcomes [11]. From an informatics
perspective, EHR implementation will permit creation of
centralized locations for clinical data, assay results, and
patient outcomes, which will benefit biomedical re-
search. Proactive use of EHR will modernize patient care
in all sectors of medicine [12]. As described by Blake
et al., for example, an EHR database featuring a universal,
user-friendly, “Google-like” informatics interface allowing
cross-talk between various infrastructures would facilitate
discovery of novel cancer biomarkers [13].
Early EHR adoption has been seen in many European
nations and domestically in private institutions including
Kaiser Permanente and government institutions such as the
VA hospital system, and increasingly widespread and rapid
adoption in the U.S. continues as a variety of vendors dis-
tribute EHR systems to medical practices of all sizes [14].
According to the National Center for Health Statistics data,
EHR use by office-based physicians has risen from 42.0% to
78.4% during the past five years [15]. This trend is corrobo-
rated by survey data from the American Hospital Associ-
ation, showing that use of EHR systems in U.S. hospitals
rose to 44% in 2012, triple the level in 2010 [16,17]. U.S.
Department of Health & Human Services (HHS) data [18]
show that health care providers participating in federal EHR
Incentive Programs reported increasing use of a wide variety
of EHR programs (Table 1), pointing toward an impending
complete transition to electronic data. While peer-reviewed
data of the myriad of EHR vendors is limited, analysis by
private groups demonstrate a fragmented market based on
factors such as ease of learning, ease of use, and practice size
(Table 1). This growth is emerging despite barriers to phys-
ician adoption of EHRs, which include financial (high
startup/upkeep costs), technical (computer skill deficits),
time (ease of learning the system), and legal (security con-
cerns) barriers to EHR implantation (Table 1) [19].
The rush to adopt EHR has led to vast amounts of
patient data entering the digital realm. A critical question
concerns how to best utilize this information to improve
patient outcomes. A systematic review of the current
impact of EHRs on a primary care healthcare system in
2011 showed that EHRs provided “structural and process
benefits”, but few data indicated improved patient
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Epic systems corporation 12.1% 19.6% +7.6% 10.2% 15.1% +4.9% 10 th
Allscripts 13.0% 11.0% −2.0% 3.4% 3.9% +0.5% 15 th/21 st/23 rd
eClinicalWorks LLC 12.4% 8.6% −3.8% N/A N/A N/A 11 th
NextGen healthcare 9.6% 8.2% −1.4% 0.6% 1.4% +0.8 27 th
GE Healthcare 6.1% 6.5% +0.5% 0.3% 0.4% +0.1 14 th/17 th
Cerner corporation 1.7% 3.7% +2.1% 15.1% 14.4% −0.7 N/A




4.9% 2.4% −2.5% N/A N/A N/A 22 nd
































most widely used [81]
% Market share for
practices of 1–3
physicians [82]
% Market share for
practices of 4–10
physicians [82]
% Market share for
practices of 11+
physicians [82]
Epic systems corporation 18 th 9 th 6 th 22% 6.4% 15.5% 25.6%
Allscripts 16 th/24 th/29 th 17 th/24 th/30 th 13 th 10% 11.0% 15.2% 15.3%
eClinicalWorks LLC 12 th 11 th 8 th 6% 13.8% 11.8% 6.4%
NextGen healthcare 30 th 26 th 17 th 5% 5.5% 5.8% 5.8%
GE Healthcare 19 th/20 th 13 th/21st 10 th 6% 6.2% 11.6% 7.7%
Cerner corporation N/A N/A 11 th 9% N/A 5.8% 15.6%




21 st 19 th N/A N/A 3.3% 3.6% N/A




28 th 22 nd N/A 1% N/A N/A N/A
“Provider” is defined as a health care professional who has (1) registered for the CMS Medicare or Medicaid EHR Incentive Programs, (2) attested to Meaningful Use as part of the CMS Medicare EHR Incentive Program,
or (3) is receiving technical assistance from the ONC REC Program in order to meet the milestones of the CMS EHR Incentive Programs. “Eligible hospital” is defined as a non-acute care hospital [16]. Primary vendors
have EHR products in a provider’s EHR system that meet the majority of “Meaningful Use” criteria; are the sole vendor of EHR products for the provider; or are vendors of a complete EHR product as reported in the
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increased completeness of patient encounters, 2) encour-
aged patient questions, 3) prevented confusion due to
illegible handwriting, and 4) bolstered confidence of clini-
cians in the EHR system [11]. Negative or adverse effects
of EHRs were: 1) no significant difference in total numbers
of patient office visits, 2) increased duplicate order entries,
3) increased incidence of insufficient EHR training, and 4)
workflow disturbances due to system crashes [11].
Randomized controlled studies have found EHRs may
negatively affect physician visualization of patient non-
verbal cues [11]. Current understanding of how EHRs
truly affect patient care is immature, but improved EHR
practices, standardization, and training to correct defi-
ciencies will optimize the effectiveness of EHRs.
EHRs have laid the foundation for clinical decision
support systems
The lack of clear evidence for positive effects of EHR
use on clinical outcomes suggests that EHR adoption is
only a first step toward improving patient healthcare
through informatics. To achieve improved outcomes via
EHR use, the best methods to digitize the massive amount
of data must be identified. The National Cancer Institute’s
now-retired caBIG program and its successor the National
Cancer Informatics Program (NCIP) serve as models for
integration of large cancer data sets. The development
and enhancement of open-source standards has enabled
cancer researchers to access up-to-date clinical data, geno-
typic data, and familial inheritance data for use in design-
ing studies and informing decisions [20]. Clinically, EHRs
are providing a wealth of information to researchers and
physicians, and early adopters have begun to integrate
clinical decision support systems (CDSS), which benefit
from the network of information provided by EHRs.
Implemented CDSS include reminder boxes for patient
follow up, warning systems for deadlines for data submis-
sion, and diagnostic suggestions.
The need for CDSS for precision medicine
CDSS are tools that incorporate established clinical
knowledge and updated patient information to enhance
patient care; they encompass an array of strategies sup-
porting a variety of topics [21]. CDSS are designed to assist
the physician-patient encounter at multiple points from
initial consultation to diagnosis to follow up (Figure 1).
Expectations are that properly equipped CDSS will sig-
nificantly benefit patient care at all levels.
CDSS promise to alleviate the ever intensifying time
demands upon physicians. Since the Affordable Care Act
has been in place, 46% of surveyed emergency medicine
physicians have seen increased numbers of patients in
emergency rooms [22]. The American Academy of Fam-
ily Physicians estimates that the number of office visitswill increase from 462 million in 2008 to 565 million by
2025 [23]. The American Association of Medical Col-
leges (AAMC) expects a shortage of 130,600 physicians
by 2025 [24]. The Social Security Administration reports
that 10,000 baby boomers reach retirement each day
[25]. The intensifying divide between supply of physi-
cians and demand on their time highlights the need for
properly designed CDSS.
Constraints on time combined with constantly-
evolving standards of care contribute to physician errors
and delayed clinical decisions [26], which directly and
adversely impact medical economics (physician error is
the largest contributor to ambulatory malpractice claims
costing an average of $300,000 per claim) [27]. Error
rates have diminished during the past 40 years, but may
still be as high as 24.4% [28]. In a 2009 analysis, 32% of
medical errors were due to inadequate time for patient
assessment, resulting in less accurate diagnosis, weighing
or prioritizing less significant analyses, or not recogniz-
ing urgency or complications [26]. Even in a modern
clinical setting supported with use of EHRs, 78.9% of
diagnostic errors were related to breakdowns in the pa-
tient/physician encounter, including 1) failure to order
required testing, 2) problems in attaining accurate medical
history, 3) inadequate patient examinations by physicians,
and 4) inadequate review of available documentation [29].
One study showed missing electronic documentation of
differential diagnoses on the index visit in 81.1% of cases
[29]. A recent report showed that 74 percent of misdiag-
noses involved cognitive errors by the physician. The most
common errors were associated with “premature closure”,
the tendency to stop considering other possibilities after
reaching a diagnosis [30]. Over a 25 year period, diag-
nostic errors accounted for 28.6% of US malpractice
claims [31].
These statistics suggest that current EHRs are popu-
lated with data points and information but have not
improved understanding or knowledge. Patient data re-
quire sequential processing by physicians to reach cor-
rect clinical conclusions, and for these conclusions to
become knowledge. These issues highlight the need for
EHR-based CDSS to translate clinical data points and in-
formation into knowledge that can be readily used by
time-constrained physicians—knowledge that would de-
crease the incidence of errors.
CDSS have been implemented in pharmacology,
pharmacy, pharmacogenomics, and pathology. Well-
characterized CDSS that assess renal function, pregnancy
status, duplicate order entry, drug allergy checking, and
determining whether a drug choice and dose is unusual
in the context of a specific diagnosis are currently used
to prevent errors in pharmaceutical dosing, drug-drug
interactions, drug-pregnancy interactions, and other
medication-related parameters [32]. In a 1994 systematic
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Figure 1 Typical office-visit workflow, highlighting points at which CDSS may improve care. Electronic health records act as a reservoir of
information used by clinicians and clinical decision support systems to plan healthcare. Along with this, information research data feeds back into
the workflow allowing a self-improving cycle of information exchange. CDSS then affects many stages of the office visit and optimizes patient
care through warnings, reminders, and suggestions.
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warning systems have improved patient outcomes through
decreased adverse effects and dosing errors [33]. One
computerized order entry support system for renal-
toxic and renal-cleared medications increased renal
function-appropriate dosing and decreased the median
length of stay by half a day [34]. These systems serve a
critical need, accounting for constantly-changing pharma-
ceutical guidelines and interactions and the substantial
numbers of subspecialty physicians interacting with an
individual patient. One prospective study showed an
86% decrease in serious medication errors after the
implantation of CDSS [35]. Case studies have identified
increased pathogen susceptibility to selected antimicro-
bial agents, decreased rates of adverse drug effects, toxic
drug levels, and bleeding events on patients taking anti-
coagulants [33].
CDSS are particularly well-suited to predicting drug-
dosing complications associated with drugs that interact
with the cytochrome P450 system, which metabolizes drugsthat have narrow therapeutic windows (e.g., Warfarin).
Future applications of CDSS will optimize drug and
dosage selection using low-cost genomic analysis to pre-
dict drug metabolism based on individual patient gen-
etic makeup [36]. A CDSS tailored to this purpose will
require a large initial data set, but once established will
permit safer, evidence-based optimal treatment and
dosing for patients.
Pathologists have swiftly adopted CDSS because the
pathology report serves as a critical decision point for
diverse specialties from preventive medicine to surgery.
Advances in histopathological analysis, EHR documenta-
tion, and cellular biology techniques have allowed for
acquisition of large amounts of digitized patient data
and, subsequently, new workflows in the digital path-
ology laboratory (Table 2) [37]. One such CDSS allows
pathologists to pool prostate cancer data and provides
prognostic and decision making tools (Table 2) [38].
Another, BRCAPRO, is a software program that pre-
dicts probabilities of carrying a deleterious mutation in
Table 2 Publications in pathology CDSS implementation
CDSS Manuscript title Topic focus Purpose Conclusions of study
CMDX©-based single source information system
for simplified quality management and clinical
research in prostate cancer [38]
Prostate Cancer Created a system used to store topographical information
about prostate sample biopsy specimens to create
heat-maps for areas of most likely to be prostatic carcinoma,
essential for clinical decision-making, prognosis, and research.
Between 2010 and 2011, generated 259 biopsy case
reports uploaded to the database with 100% data
completeness and a source-to-database error of 10.3
per 10,000 fields. Serves as an implementation of
pathology data sharing through a healthcare
information system.
A Teaching Database for Diagnosis of Hematologic




Developed of web-enabled relational database, by pooling
literature for cell surface marker definitions of 37 hematologic
neoplasms. Using this expression profile, an algorithm was
created by pathologists to assist in teaching flow cytometry
diagnosis of hematologic neoplasms
Algorithm for identifying hematologic marker
expression patterns validated using 92 clinical cases
with an identification success rate of 89%. Tool has
been used by pathologists-in-training to develop
flow cytometry interpretation skills.
Bayesian belief network for the Gleason patterns
in prostatic adenocarcinoma: development of a
diagnostic decision support system for educational
purposes [85]
Prostate Cancer Developed a Bayesian belief network (BBN) for Gleason
grading of prostate adenocarcinoma, to allow subjective
evaluation of prostatic carcinoma slides by computer.
As histological diagnosis of prostate carcinoma is
often produces wide inter-interpreter variability.
This tool serves as a decision support tool to interpret
descriptive terms in pathology reports and accurately
determine tumor grading.
A computer-based diagnostic and prognostic
system forassessing urinary bladder tumour grade
and predicting cancer recurrence [86]
Bladder Cancer Designed a decision support system, employed by pathologists
in microscopic observation of tissue samples
and measurements of nuclear characteristics, allowing
automatic assessment of urinary bladder tumor grade and
cancer recurrence probability.
The system employed classified tumors with an
accuracy of 82%, 80.5%, and 93.1% for tumors of grade
I, II, and III. Suggested prognosis in 72.8% of samples
with a confidence of 74.5%.
Comprehensive graphic-based display of clinical
pathology laboratory data [87]
Information Sharing Established a graphic-based computerized system for
display of clinical pathology data to permit improved
data access and sharing.
By displaying laboratory data in a graphical manner,
designers aimed to create a user-friendly system meant
to highlight pertinent trends necessary for decision
management.
Electronic reminders for pathologists promote
recognition of patients at risk for Lynch syndrome:
cluster-randomised controlled trial. [88]
Colorectal cancer Deployed a new guideline to improve recognition of
patients at risk for Lynch syndrome by a multidisciplinary
team of surgeons, pathologists and clinical geneticists.
An electronic reminder system for pathologists
increasing identification of patients at high risk for
Lynch syndrome by 18% when compared to the
control arm.




Developed an image based retrieval system containing
261 digitized images of lymphocyte disorders and regular
lymphocytes. Queries to the system extract features of the
histopathological images for comparison and identification.
Based solely on morphological characteristics, the
analysis system performed better than humans in
identifying certain lymphoproliferative disorders
according to a ten-fold cross-validated confusion
matrix.
Selected manuscripts focused upon clinical decision support for pathologists. Ranging from image identification to computerized reminders, the potential for decision support is broad. The purpose of each support
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upon patient cancer status and family history of breast
and ovarian carcinoma [39]. BRCAPRO is highly sensitive
for screening, and illustrates the immense potential of
clinical informatics to guide preventive medicine and im-
prove patient outcomes [39]. These examples in pharma-
cology and pathology, along with others highlighted in
Table 2, illustrate the potential benefits of informatics for
clinical decision support.Why current CDSS are inadequate and the role
they must fill
Despite promising initial data from the two aforemen-
tioned fields, the majority of CDSS have not provided
features beyond general alerts, reminders, summary
dashboards, and automated information retrieval sys-
tems [40,41]. A majority of United States hospitals have
yet to implement any form of CDSS. “Comprehensive”
EHR systems are those that include decision support
features (clinical guidelines, clinical reminders, drug-
allergy alerts, drug-drug interaction alerts, drug labora-
tory interaction alerts, drug-dosing support); only 1.5%
of 2952 hospitals surveyed achieved a “comprehensive”
classification [42]. Few studies of CDSS have shown any
improvement in outcomes, and any such effects seen
have achieved only low statistical significance [40]. A
meta-analysis of 148 randomized clinical trials on CDSS
implementation found that only 20% influenced clinical
outcomes [41]. Of these, improvements were seen in
morbidity outcomes such as number of hospitalizations,
surgical site infections, cardiovascular events, and deep
vein thrombosis, but there was little effect on mortality
or pharmacologic adverse events [41], suggesting that
CDSS will need improvement before they can routinely
provide clinically meaningful knowledge.
Scientific and clinical data sets are typically located in
extremely large files located in different databases
worldwide (“information silos”). To convert endless data
points and relevant information into forms easily
reviewed by physicians and researchers, information
silos must be connected. Intelligent algorithms must
apply standardized languages/phenotypes to decide
which pieces of information may be relevant to a spe-
cific query. If the vast amount of patient data currently
present in hospital EHR databases is considered as an-
other information silo, then how would connections be
made from patient data to primary literature for both
scientific and clinical use? A truly useful CDSS would
combine data points and information generated from
thousands of hours of research, clinical assays, blood
work, and follow up data to reach the clinical endpoint.
Bridging of knowledge between these realms embodies
the idea of collaboration in medicine.Evolution from data, to processed information, to
integrated knowledge, to expert systems
In the early days of computing, digitized data were stored
in files, later in databases, and now in data warehouses
and, via the internet, in “the cloud”. Data capacity and
storage have become massive, paving the way for current
“big data” paradigms and initiatives that promise to pro-
vide answers to increasingly complex and challenging
scientific and medical questions. The key barriers to
progress are the disparate and dispersed nature of “big
data”. The challenge is to develop means for integrating
or querying across the relevant information silos to gain
needed insights and problem solutions.
Scientific research in diverse arenas yields in-depth
results representing new data and interpretive information
that is generally distributed to other scientists via pub-
lications in scientific journals and entry into databases.
The vertically-organized nature of such knowledge
tends to sustain data within silos that contribute to
access barriers, resisting facile integration and query-
ing of data. Therefore, to effectively leverage new
scientific discoveries, and broaden understanding by
scientists working in disparate fields, a tool to interro-
gate data across the existing information silos is critic-
ally needed.
A common and useful method for integrating dis-
parate data sources is to apply standard vocabularies
and data formats, with the goal of reducing complexity
and technical barriers to their integration across fields
of specialization. Fortunately, scientific information is
extremely standardized, and data formatting is also
guided and regulated by US national agencies, including
the National Institute of Standards and Technologies
(NIST) and the National Institutes of Health (NIH)
[43]. Standards for clinical data points and information
contained in EHRs and various clinical reports in forms
of paper-based physician or patient charts have been de-
veloped by Health Level Seven International (HL7), the
World Health Organization International Classification
of Disease (ICD9, ICD10, and ICD-O), and the Inter-
national Health Terminology Standards Development
Organization (SNOMED) [44]. To permit integration of
genomic data into CDSS and to describe data around
biological concepts, integrating resources such as Gene
Ontology (GO) and HUGO Gene Nomenclature will be
necessary.
As knowledge advances, the terms used to communi-
cate such knowledge must be aligned and integrated into
the knowledge foundation represented by accepted stan-
dards. Also, new standards must be applied to existing
data in a manner allowing comparisons between current
and historical data. Ongoing discussions required to de-
velop such standards are significant and substantive, and
can be tedious, arduous, and controversial. Continuously
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adoption, but effective implementation of these ‘inter-
nationally accepted’ standards is required to accelerate the
use of CDSS and to enhance the quality of patient care.
New research platforms such as those driven by vari-
ous genomic and other “-omic” technologies generate
massive amounts of raw data that require analysis using
biostatistical methods and a range of visualization tools.
Information from new platforms is often difficult to
relate to data generated by other platforms. To address
this issue, commercial software companies have devel-
oped suites of powerful tools focused on platform-
specific data (Table 3). For example, large datasets of
gene expression experimental results are stored in the
NCBI Gene Expression Omnibus (GEO) [45]. Several or-
ganizations and companies have developed effective and
innovative ways to mine disparate gene expression data
in GEO, which enables researchers to access and analyze
valuable information (Table 3). Such domain-specific
systems are built on database technologies that allow
information from different databases to be logically
linked, providing additional and enriched capabilities to
researchers.
The concept of an integrated knowledge environment
is based on connecting structured but disparate database
repositories with information stored in unstructured,
text-based repositories and databases. Narratives and
descriptions of specific domains (e.g., gene expression
profiles, cell signaling pathways, Next Generation Se-
quencing (NGS), mutations) provide accurate, efficient
means for connecting information stored in classic data-
base schemas. In the federated database approach, a
metadata layer links disparate databases permitting inte-
grating, mining, and searching all types of information.
The metadata is structured information that describes
and links the underlying data sources; it describes the
data elements, can define the structure of the data, and
can define the administrative information such as when
the data was generated and by whom. The metadata
layer may utilize existing standards or may employ de
novo standards appropriate to the underlying data
sources [46]. An important metadata concept for scien-
tific and medical data is the ability to assign confidence
to the data sources, allowing a user to determine
whether the accessed data is actionable in a clinical or
research setting. Since data definitions and structures
evolve over time, generation of a metadata layer requires
a flexible data model that describes the objects and data
elements contained in various sources [46,47]. Applica-
tion of common standards allows disparate information
to be mapped so as to expose valid semantic and scien-
tific relationships. Such lateral, cross-cut information
views allow relevant relationships to be visualized within
network maps. Visualization by network maps provideslayers of information about biological activities, disease
progression, mechanisms of action, and pathways that
can enhance analysis of the evidence necessary to pro-
vide input into a CDSS (Figure 1) [48].
Supercomputers, artificial intelligence, and medicine
IBM’s Watson supercomputer captured the imagination
of the world when it beat two reigning champions on
the television quiz-show Jeopardy in 2011 [49]. This
achievement represented a significant milestone in
computer science, because the Jeopardy game requires
abstraction and ‘understanding’ natural language. Due to
the structure of the questions, Watson could not simply
reference databases of pre-computed questions and
answers but had to use the Deep QA architecture, creat-
ing hypotheses based on sources, referencing sources for
evidence, scoring the evidence, and synthesizing the data
into a final ranking [50,51]. The system’s critical function
is its analytic process. The computer must weigh rele-
vant parameters for each item of reference material and
construct a summarized interpretation yielding a conclu-
sion. For example, how should a particular statement in
a diabetes textbook be weighted relative to a recently-
published article on diabetes? How should the system
resolve conflicting information? One method to address
these concerns is to train Watson through experience.
Experiential training allows artificial intelligence systems
such as Watson to 1) translate data points (first tier) to
information (second tier), 2) convert information to
clinically relevant and meaningful knowledge (third tier),
and to 3) achieve expert understanding (fourth tier).
The current approach is to enter scenarios and case re-
ports that have been annotated by medical professionals
highlighting best answers or most likely diagnoses, train-
ing the system to recognize classical presentations of
disease [52]. This approach is working; in statements by
David Ferrucci, Watson principle investigator, Watson
is currently out-diagnosing medical residents in selected
criteria [53]. Adding training and additional content to
Watson has improved its accuracy in answering American
College of Physician clinical question sets by 28% [51].
A second approach to training the supercomputer is
to feed the system thousands of medical records and
diagnoses, enabling it to analyze trends and associations
hidden in physician notes, laboratory data, genetic data,
and other records. IBM has partnered with speech-
recognition software companies, health benefits com-
panies, and other institutions to develop training for
CDSS that fully encompasses the entire physician-
patient interaction from healthcare outcomes to EHRs
[54-56]. News releases by IBM state this approach is
being used in the development of personalized cancer
therapy at MD Anderson [55]. Nonetheless, system
training incorporating only clinical presentations and




Purpose License Update method # of databases Databases integrated Company
Atlas [90] “A biological data warehouse called
Atlas that locally stores and integrates
biological sequences, molecular
interactions, homology information,
functional annotations of genes, and
biological ontologies”.
Open Source Manual 13 GenBank, RefSeq, UniProt, Human
Protein Reference Database (HPRD),
Biomolecular Interaction Network
Database (BIND), Database of
Interacting Proteins (DIP), Molecular
Interactions Database (MINT), IntAct,
NCBI Taxonomy, Gene Ontology
(GO), Online Mendelian Inheritance in
Man (OMIM), LocusLink, Entrez Gene
and HomoloGene
British Columbia
University - Vancouver, BC
Biowarehouse [91] “An open source toolkit for constructing
bioinformatics database warehouses
using the MySQL and Oracle relational
database managers. Integrates multiple
public bioinformatics databases into a
single relational database system
within a common bioinformatics
schema”.
Open Source Dependent on the
individual databases
12 ENZYME, KEGG, BioPax, Eco2dbase,
Metacyc, Mage-ML and BioCyc,
UniProt, GenBank, NCBI Taxonomy,
CMR databases, and Gene Ontology.
Stanford Research
Institute – Menlo Park, Ca
Columba [92] “Facilitates the creation of protein
structure data sets for many
structure-based studies.
It allows combining queries on a
number of structure-related databases
not covered by other projects at
present”.
Free-Use Dependent on the
individual databases
12 PDB, SCOP, CATH, DSSP, ENZYME,
Boehringer, KEGG, Swiss-Prot, GO,
GOA, Taxonomy, PISCES
Humboldt-Universität zu
Berlin – Berlin Germany
Systomonas [93] “To provide an integrated
bioinformatics platform for a systems
biology approach to the biology of
pseudomonads in infection and
biotechnology”.
Free-Use Unknown 4 KEGG, Pseudomonas Genome




Oncomine [94] “A cancer microarray database and
web-based data-mining platform






Annually for Free Version,
Regular data updates for
subscription
- 65 Gene expression datasets, from
4700 microarray experiments.
Life Technologies Corporation
Biomart [95] “BioMart enables scientists to perform
advanced querying of biological data
sources through a single web interface.
The power of the system comes from
integrated querying of data sources
regardless of their geographical
locations”.
Open Source Unknown 25 (as of 2009),
46 as of 5/2014
Ensembl Genes, Ensembl Homology,
Ensembl Variation, Ensembl Genomic
Features, Vega, HTGT, Gramene,
Reactome, Wormbase, Dictybase,



















Table 3 Overview of software systems designed to integrate data from multiple databases (Continued)
Ondex [96] “The Ondex data integration platform
enables data from diverse biological
datasets to be linked, integrated and
visualised through graph analysis
techniques. Ondex can be used in a
number of important application
areas such as transcription analysis,
protein interaction analysis, data
mining and text mining”.
Open Source Unknown 28 AraCyc, AtRegNet, BioCyc, BioGRID,
Brenda, Cytoscape, EcoCyc, GOA,
Gramene, Grassius, KEGG, Medline,
MetaCyc, O-GlycBase, OMIM, PDB,
Pfam, Prolog (limited functionality),
SGD, TAIR, TIGR, Transfac, transpath,




InterMine [97] “InterMine is an open-source data
warehouse system that facilitates
the building of databases with
complex data integration requirements
and a need for a fast customizable
query facility. Using InterMine, large
biological databases can be created
from a range of heterogeneous data
sources, and the extensible data model
allows for easy integration of new data
types”.
Open Source Unknown 23 GO Annotation, GO OBO, Treefam,
Homologene, OrthoDB, Panther,
Ensembl, Compara, BioGRID, IntAct,
PSI-MI Ontology, KEGG, Reactome,
UniProt, Protein Data Bank, InterPro,
PubMed, Ensembl SNP, Chado,





Scan-MarK [65] “An integrated, growing biomarker
repository of over 2,000 breast, ovarian,
colorectal, non-Hodgkin’s lymphoma and
melanoma biomarkers mined and
manually curated by PhD. scientist from
full-text papers. Annotations include 33
critical data elements (CDEs) organized
in computable Sophic Cancer Biomarker
Objects (SCBOs). SCan-MarK allows
researchers to mine, explore and expose
complex biomarker, disease, treatment,
outcome relationships graphically
displayed as knowledge networks”.
Free Trial Manual 30 Examples: TCGA, dbSNP, Cancer
Gene Index, Drugbank, PDB, Sophic’s
non-redundant Sanger COSMIC,
Medline, ENSEMBL, ENZYME, Go,





Displayed are current software solutions whose primary goal is to facilitate research workflow through data-mining algorithms. These software solutions range from open-source to paid subscription, and target specific
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data will provide a less than desirable outcome. The
ultimate goal will be to incorporate both clinical and
scientific data, which will facilitate analysis that fully
encompasses the entire laboratory-physician-patient inter-
action from genotype to clinical outcome.
Why is Watson important in clinical medicine?
Watson’s implementation marks the development of the
first large-scale, integrated CDSS capable of processing
both structured and unstructured information to suggest
possible differential diagnoses. This artificial intelligence
system addresses two primary reasons for physician
error: 1) premature closing of diagnosis (defined earlier)
and 2) failure to consider all other possibilities [31].
While peer-reviewed literature is not available due to the
youth of this partnership, Wellpoint Inc. states Watson’s
support of utilization management decisions in 1,500
cases has shown encouraging results [56].
As computing technology moves forward, the unprece-
dented algorithm enabling interpretation of natural lan-
guage by CDSS systems will directly assist analysis of
primary literature, reducing the need for manually-curated
sets of rules that are often limited in topic or scope. By
allowing systems such as Watson to analyze information
such as patient notes, laboratory data, genotype data, and
familial inheritance data, individualized clinical and mo-
lecular profiles of each patient can be assembled. The indi-
vidualized patient profile can then be compared to the
thousands of other patient EHRs to identify similarities
and associations, thus, elucidating trends in disease course
and management. Each new and validated association
extends the foundation of the Watson architecture and
facilitates increased confidence in subsequent output for
diagnoses. These strengths and progress represent a sig-
nificant advance in the field of clinical informatics.
Although it has received widespread recognition and
media coverage, IBM’s Watson is not alone; a number
of other players in the field of medical informatics
supercomputing have also emerged. Alternative analytic
systems such as Hadoop, an open source software
framework for large dataset analysis, are already being
used in BLAST multiple sequence alignment and in the
topological analysis of immense genotype datasets [57].
The advance in semantic-oriented analytic software is
also exemplified in the development of Wolfram Alpha,
a knowledge engine infrastructure used to evaluate and
interpret datasets ranging from higher mathematics to
engineering [58]. Interpretation of English language
queries by Wolfram Alpha draws parallels to the natural
language processing capabilities of IBM’s Watson. Appli-
cation to the field of clinical informatics seems inevitable;
asking Wolfram Alpha “How should I treat the common
cold?” returns data on the most commonly prescribeddrugs, sorted by drug class. In fact, Wolfram’s program
language already includes functions to manipulate
genome data and parse protein databases [59]. The un-
developed nature of this field has opened the door to
the emergence of a wide variety of supercomputing
algorithms and frameworks.
While promising, this technology is still new, and
continuing input from clinicians, patients, and other
stakeholders will be essential for correctly implementing
the technology [60]. System development is costly, and
requires substantial hands-on training for optimal use.
According to Wellpoint Inc., nurses have already spent
over 14,700 hours training Watson [61]. A critical ques-
tion is whether such costs are justified. Does Watson or
similar artificial intelligence-based CDSS effectively and
efficiently improve patient outcomes?
The prospect of artificial intelligence-based CDSS and
their role as the umbrella of all scientific and clinical
data depends on a dedicated roadmap and investments
from the government and public and private sectors.
Deployment of a mature Level 4 EHR is expected to cost
$28 billion dollars per year over a 10 year adoption
period [62]. Private research firms estimate Watson’s ini-
tial development costs to be somewhere between $900
million and $1.8 billion dollars [63]. Significant invest-
ments may be required to achieve widespread use of
artificial intelligence-based CDSS in the clinical setting.
How data integration affects medical research
Improved patient outcomes are the most immediate
endpoint of CDSS, but information and data output
need to flow back to researchers. As in clinical medicine,
time and manpower in laboratories are precious resources.
Integration of the biomedical community through transla-
tional bioinformatics is important [12,64]. Systems such as
Hugenet, an aggregation of genomic data with environ-
mental and public health registries [64], and SCanMarK
Explorer, an integrated knowledge environment that in-
cludes a manually curated cancer biomarker database [65],
have been created within focused specialized topic areas.
These and other similar software platforms provide re-
searchers with valuable and integrated databases upon
which models can be designed and research furthered
(Table 3) [12]. Despite these advances, a pressing concern
is the task of keeping these integrated databases up-to-
date. Astonishingly, the current state-of-the-art for updat-
ing many of these integrated knowledge environments is
nothing more than manual data entry (Table 3).
Major cancer centers at Massachusetts General Hospital
and Memorial Sloan Kettering are already using next
generation sequencing technologies to integrate patient
specific genomic information with research data to gen-
erate the foundation of personalized cancer treatment
plans [66]. Use of EHRs will have become mandatory in
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that becomes available will need to be integrated. As
more outcomes data become available, researchers will
need access to it [64]. This bidirectional flow of infor-
mation promises to decrease the time between labora-
tory discovery and clinical implementation. Electronic
integration between clinics and scientists can expedite
research impacts. For example, Vioxx (Rofecoxib) was
approved by the FDA in 1999 and released by Merck
for pain management, with the promise of decreased
adverse gastrointestinal symptoms. However, in 2003,
an increased risk of myocardial infarctions within
90 days of beginning treatment was identified, ultim-
ately causing worldwide withdrawal of the drug in 2004
[67]. The discovery and quick action taken was primar-
ily due to Kaiser Permanente’s early support of patient
databases and registries, which allowed researchers and
physicians to assess long-term patient outcomes. The
system allowed physicians to immediately access data
for research and to receive instant feedback [14].
Concerns in digitalization and integration of health
records and databases
The rapid expansion of computerization into the health-
care arena raises many ethical and legal concerns with re-
spect to privacy, confidentiality, and data exchange. From
a moral perspective, the most pressing concern to the gen-
eral public and healthcare systems alike is whether geno-
type data and more generally digitized data can be made
truly secure. The problem with this is that genotype data
is inherently not private [68]. The identity of a patient with
a rare genetic condition would easily be identified amongst
a database of persons without said disease. This engenders
concerns regarding potential controversial practices such
as discrimination based on genetics against patients by in-
surance companies [68,69]. These issues have been recog-
nized by the US Government, and legislation such as the
Genetic Information Nondiscrimination act of 2008 and
the 2010 Patient Protection and Affordable care act in-
clude provisions to protect against genetic discrimination
[70]. Even the National Institutes of Health has removed
SNP data from publically available databases in an effort
to protect research participant privacy [71]. These actions
are a promising start, but the ethical ramifications of mer-
ging databases containing genomic information with data-
bases containing patient data have yet to be addressed.
How should researchers handle informed consent in the
case of incidental findings on patient genomic data [72]?
How should genomic data shared between researchers be
handled? The issue of confidentiality must be properly
addressed in order to allow continued genomic research
and collaboration [69].
From a technological standpoint, a survey of US
Healthcare institutions by a private data security groupshowed that up to 40% of those institutions lacked confi-
dence in the security of health information exchange
systems including EHRs [73]. Understanding how to
ensure privacy and security is a key challenge. The ex-
perience has been rocky. A data breach in 2010 exposed
data of 6,800 patients to internet search engines [74]. A
breach in 2013 exposed data of 32,000 patients due to
failure of a security firewall [75]. Complicating matters is
the wide range of mobile devices that can store patient
data. A stolen physician’s laptop in 2012 contained
patient data [76]. Each of these breaches resulted in costly
settlements. Companies have stepped forward to address
the security needs of EHRs. For example, BlackPhone, a
mobile smartphone focused on security and data exchange
[77], decreases electronic exposure risk through encrypted
voice calls and texts. Such technologies have natural
applications to the sensitive data routinely transferred
within hospitals, and their implementation may help
prevent costly data breaches and HIPAA violations.
Finally, from a logistical perspective, the wide variety
of implementations and permutations of electronic health
records will challenge data exchange both amongst health-
care providers and between healthcare providers and
researchers. The benefits of healthcare information
exchange are clear. Reducing: laboratory redundancy,
imaging redundancy, and administrative costs are a few
of the theoretical advantages [62]. As a result, patient
safety stands to improve in a number of different ways
[78]. The problem lies in that electronic health systems
were not built with the goal of being interoperable, they
were built with the goal of meeting meaningful use
standards [79]. Furthermore, data on the exact struc-
ture and syntax by which these different EHR systems
operate is limited [4]. Due to these differences, a funda-
mental framework for connecting these silos of health-
care information is lacking, and therefore, poses one
more challenge to the goal of an integrated information
network.
Conclusions
We have entered an era where use of computers, tablets,
and smart phones allow the capture of nearly all infor-
mation in digital format. The challenge is not “How can
we collect all of these data?” but “How can we integrate,
secure, and utilize this large amount of data via CDSS to
improve clinical outcomes?” Computer-based systems
that can host all scientific and clinical data are critical to
generating the end-point knowledge that is directly rele-
vant to improved understanding and management of
disease for each patient. As supercomputing, science,
and medicine continue to converge, the conversion of
data to knowledge, and sharing of such knowledge, has
become a crucial component for achieving precision
medicine and personalized patient care.
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